The ReChord Trial is an investigational treatment option for patients diagnosed with degenerative mitral valve regurgitation.

SCRI Cardiovascular ReChord Trial


Mitral Valve Insufficiency

Study Name:

Randomized Trial of the NeoChord™ DS1000™ System Versus Open Surgical Repair (The ReChord Trial)

Trial Descriptor:

The ReChord Trial is a prospective, randomized, clinical trial to assess the safety and effectiveness of the NeoChord DS1000 System for the treatment of patients with moderate or severe degenerative mitral regurgitation.

Trial Objective:

The objective of the ReChord Trial is to assess the safety and effectiveness of the study device in subjects with degenerative mitral valve disease receiving a mitral valve repair without cardiopulmonary bypass (treatment group) when compared to subjects receiving mitral valve repair using standard surgical techniques with cardiopulmonary bypass (control group).

Key Inclusion Criteria:

  • Indication for isolated surgical mitral valve repair per ACC/AHA and ESC/ EACTS Guidelines
  • Moderate or severe degenerative mitral valve regurgitation
  • Segmental prolapse of the A2 or P2 segment
  • Anterior leaflet covers at least 65% of anterior-posterior annular distance

Key Exclusion Criteria:

  • Prior mitral valve surgery
  • Concomitant cardiac procedures
  • Other cardiac procedures within 3 months

Principle Investigators:

  • Dr. Alessandro Golino
  • Dr. Gino Sedillo
  • Dr. Ashok Krishnamurthy

For additional information, visit or Identifier NCT02803957.

If you have any further questions, contact our Cardiovascular Clinical Research Coordinator, Arika Manapat, MS at
(941) 798-6509 or email.